1,080
Participants
Start Date
September 23, 2022
Primary Completion Date
June 21, 2023
Study Completion Date
June 21, 2023
V116
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
QIV
Single 0.5 mL IM injection
Matching Placebo for V116
Single 0.5 mL of sterile saline IM injection
Synexus Clinical Research US, Inc - New York ( Site 0053), New York
Smith Allergy and Asthma Specialists-Certified Research Associates ( Site 0019), Cortland
Meridian Clinical Research, LLC ( Site 0032), Vestal
Rochester Clinical Research, Inc. ( Site 0055), Rochester
Hatboro Medical Associates / CCT Research ( Site 0065), Hatboro
Centennial Medical Group ( Site 0035), Elkridge
M3 Wake Research Associates ( Site 0040), Raleigh
Carolina Institute for Clinical Research ( Site 0047), Fayetteville
Velocity Clinical Research, Columbia ( Site 0058), Columbia
Velocity Clinical Research, Anderson ( Site 0077), Anderson
East Coast Institute for Research - Canton ( Site 0004), Canton
Clinical Research Atlanta ( Site 0068), Stockbridge
East Coast Institute for Research, LLC ( Site 0013), Jacksonville
Optimal Research ( Site 0008), Melbourne
Velocity Clinical Research, Hallandale Beach ( Site 0064), Hallandale
Indago Research & Health Center, Inc ( Site 0029), Hialeah
Lakes Research ( Site 0063), Miami Lakes
Suncoast Research Group-Clinical Department ( Site 0062), Miami
Suncoast Research Associates ( Site 0041), Miami
Alpha Science Research ( Site 0042), Miami
Triple O Research Institute, P.A ( Site 0054), West Palm Beach
Health Awareness ( Site 0034), Jupiter
Clinical Research Associates Inc ( Site 0026), Nashville
Holston Medical Group-Clinical Research ( Site 0028), Bristol
Holston Medical Group-Clinical Research ( Site 0009), Kingsport
CTI Clinical Research Center ( Site 0071), Cincinnati
Healthcare Research Network - Chicago ( Site 0014), Flossmoor
Synexus Clinical Research US, Inc. ( Site 0072), Chicago
Healthcare Research Network - St. Louis ( Site 0011), St Louis
Radiant Research ( Site 0073), St Louis
Alivation Research-Primary Care ( Site 0066), Lincoln
Benchmark Research ( Site 0025), Fort Worth
New Horizon Medical Group ( Site 0078), Houston
Innovative Medical Research of Texas ( Site 0079), Houston
LinQ Research ( Site 0074), Pearland
Headlands Research - Brownsville ( Site 0069), Brownsville
Optimal Research ( Site 0015), Austin
Alliance for Multispecialty Research, LLC ( Site 0051), South Jordan
Synexus Clinical Research US, Inc. ( Site 0001), Murray
Central Phoenix Medical Clinic-Synexus Clinical Research US ( Site 0012), Phoenix
Axces Research ( Site 0037), Santa Fe
WR-CRCN, LLC ( Site 0018), Las Vegas
Hope Clinical Research, Inc. ( Site 0070), Canoga Park
Valley Clinical Trials, Inc. ( Site 0002), Northridge
Carbon Health - North Hollywood - NoHo West ( Site 0016), North Hollywood
Catalina Research Institute, LLC ( Site 0067), Montclair
Paradigm Clinical Research Centers, Inc ( Site 0024), La Mesa
Artemis Institute for Clinical Research ( Site 0023), San Diego
WR-MCCR, LLC ( Site 0033), San Diego
California Research Foundation ( Site 0005), San Diego
WR- PRI, LLC ( Site 0044), Newport Beach
Diablo Clinical Research, Inc. ( Site 0020), Walnut Creek
Velocity Clinical Research, Medford ( Site 0060), Medford
Arthritis Northwest, PLLC ( Site 0059), Spokane
Velocity Clinical Research, Spokane ( Site 0050), Spokane
Velocity Clinical Research, Providence ( Site 0021), East Greenwich
Merck Sharp & Dohme LLC
INDUSTRY